MedTrace Logo

Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.

NCT03119519 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2020-03-18

No results posted yet for this study

Summary

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

Conditions

  • Stage IV Non-small Cell Lung Cancer

Interventions

RADIATION

Local Definitive Radiotherapy

three-dimensional conformal therapy or intensity modulated radiation therapy

DRUG

No Local Definitive Radiotherapy

Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.

Sponsors & Collaborators

  • Southern Medical University, China

    lead OTHER

Principal Investigators

  • Xiaoxia Zhu · Nanfang Hospital, Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2020-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119519 on ClinicalTrials.gov